Back to top
more

Alkermes (ALKS)

(Delayed Data from NSDQ)

$29.24 USD

29.24
1,523,282

+0.01 (0.03%)

Updated Nov 13, 2024 04:00 PM ET

After-Market: $29.24 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Implied Volatility Surging for Alkermes (ALKS) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Alkermes (ALKS) stock based on the movements in the options market lately.

Here's Why Alkermes (ALKS) Is a Great 'Buy the Bottom' Stock Now

by Zacks Equity Research

Alkermes (ALKS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Factors That Make Universal Health (UHS) an Attractive Bet Now

by Zacks Equity Research

Universal Health (UHS) remains well-poised for growth on the resumption of elective surgeries, a diversified treatment network and solid cash reserves.

Caribou Biosciences (CRBU) Soars on $25M Investment by Pfizer

by Zacks Equity Research

Caribou Biosciences (CRBU) gets a major boost with a $25 million equity investment by Pfizer, which will accelerate the development of its allogeneic CAR-T cell therapy pipeline.

Here's Why You Should Add Alkermes (ALKS) to Your Portfolio

by Zacks Equity Research

Alkermes (ALKS), a top-ranked stock, has a diverse portfolio of neurological therapies. Its proprietary products are witnessing incremental sales.

Is Alkermes (ALKS) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Alkermes (ALKS) and Masimo (MASI) have performed compared to their sector so far this year.

Alkermes (ALKS) Gets Final Award in Janssen Arbitration, Ups View

by Zacks Equity Research

Alkermes (ALKS) receives final award in arbitration proceedings with partner Janssen. It also raises its financial outlook for 2023.

Allogene Therapeutics (ALLO) Down 17.5% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Sarepta Therapeutics (SRPT) Down 1.5% Since Last Earnings Report?

by Zacks Equity Research

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Vertex (VRTX) Down 6% Since Last Earnings Report?

by Zacks Equity Research

Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Alkermes (ALKS) Up 3.7% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Alkermes (ALKS) Q1 Earnings & Revenues Beat Estimates

by Zacks Equity Research

Alkermes (ALKS) reports encouraging first-quarter results, wherein both earnings and revenues beat estimates. This is due to strong growth in commercial execution of its proprietary products, Lybalvi and Vivitrol.

Alkermes (ALKS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

Although the revenue and EPS for Alkermes (ALKS) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Alkermes (ALKS) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Alkermes (ALKS) delivered earnings and revenue surprises of 133.33% and 1.18%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Acadia (ACAD) Down 10.9% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Alkermes (ALKS) Stock Up 15% in Six Months: Here's Why

by Zacks Equity Research

Alkermes shares have surged in the past six months, owing to strong sales performance of its new drug Lybalvi and its decision to separate the oncology unit.

Alkermes (ALKS) Q4 Earnings & Sales Top Estimates, Stock Up

by Zacks Equity Research

Alkermes' (ALKS) earnings and sales beat estimates in the fourth quarter of 2022.

Alkermes (ALKS) Beats Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Alkermes (ALKS) delivered earnings and revenue surprises of 180% and 6.24%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Verona (VRNA) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Devoid of marketed drugs, investors' will focus on Verona Pharma's (VRNA) lead pipeline candidate when it reports its fourth-quarter earnings.

Drug/Biotech Stocks Q4 Earnings Due on Feb 16: ALKS, RARE & Others

by Zacks Equity Research

Let's look at the four biotech/drug companies slated to release quarterly results on Feb 16.

Exelixis (EXEL), Sairopa Obtains IND Clearance for ADU-1805

by Zacks Equity Research

Exelixiss' EXEL) partner Sairopa gets FDA clearance for its IND application for the oncology drug ADU-1805, a potential best-in-class monoclonal antibody for adults with advanced solid tumors.

Syndax (SNDX) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Devoid of marketed drugs, investors' focus will be on Syndax Pharmaceuticals' (SNDX) pipeline progress when it reports its fourth-quarter earnings.

Incyte (INCY) Reports Positive Long-Term Data From HS Study

by Zacks Equity Research

Incyte's (INCY) povorcitinib shows sustained and durable efficacy across all treatment arms in the open-label extension period of the phase II HS study.

Blueprint's (BPMC) Cancer Study Put on Partial Hold by FDA

by Zacks Equity Research

Blueprint's (BPMC) early- to mid-stage study for the treatment of patients with CDK2-vulnerable cancers put on partial clinical hold by the FDA.

Assertio (ASRT) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

On Assertio Holdings' (ASRT) Q4 earnings call, investors will focus on the sales performance of its marketed products.